May 7, 2024- Thermo Fisher has released a simple, urine-based assay that detects the CXCL10 chemokine may make care more convenient and less invasive for the nearly 250,000 Americans living with a kidney transplant. For organ transplant recipients, life post-transplant involves a delicate balance between invasive monitoring and immunosuppression to reduce the risk of rejection, both of which may carry complications.
Thermo Fisher Scientific One Lambda Laboratories, a CLIA facility in Fishers, Ind., has introduced a new CXCL10 testing service, which allows for non-invasive urine sample collection and testing, with results available in as little as 24 hours, providing valuable information faster than currently used tests.
Multiple studies have shown that elevated urinary CXCL10 levels are associated with inflammation and early kidney transplant rejection, as outlined in a recent article in Current Opinion in Organ Transplantation.